DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
Status:
Not yet recruiting
Trial end date:
2028-09-30
Target enrollment:
Participant gender:
Summary
DURANCE is a two part, phase Ib/II, multi-centre study to assess the safety and activity of
S-488210/S-488211 in combination with durvalumab, in patients with non-muscle invasive
bladder cancer (NMIBC).